Thus, although the mutational burden of tumor cells may increase their antigenicity, it may also enhance their ability to evade treatment-induced immune responses [16] by interfering with the expected proapoptotic effect of PD-1/PD-L1 blocking therapies and receptor kinases inhibitors. This evidence concerns the gene PDCD1 and neoplasm.